ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Keyword Index

Click a keyword to view all the abstracts on this site tagged with that keyword.

  • anti-citrullinated protein/peptide antibodies (ACPA) and therapeutic targeting
  • anti-cN1A antibodies
  • Anti-depressant
  • Anti-DNA
  • anti-DNA and antibodies
  • anti-DNA and lupus nephritis
  • Anti-drug antibodies
  • anti-drug antibodies and anti-TNF therapy
  • anti-dsDNA
  • anti-dsDNA and anti-Smith
  • anti-dsDNA and cytokines
  • anti-dsDNA and glomerulonephritis
  • anti-dsDNA and immunoglobulin (IG)
  • anti-dsDNA and nephritis
  • anti-dsDNA and neuropsychiatric disorders
  • anti-dsDNA and Reproductive Health
  • Anti-GBM Disease (Goodpasture's)
  • Anti-histone antibodies
  • Anti-La
  • anti-mitochondria antibody
  • anti-mitochondria antibody and calcinosis
  • anti-mitochondria antibody and prognostic factors
  • Anti-MPP1
  • anti-mutated citrullinated vimentin
  • anti-phosphatidylserine/prothrombin antibodies
  • Anti-resorptives
  • anti-ribosomal P
  • anti-RNA antibodies
  • Anti-Ro
  • Anti-Synthetase Syndrome and malignancy
  • Anti-TNF Drugs
  • anti-TNF therapy
  • anti-TNF therapy and arthritis
  • anti-TNF therapy and axial spondyloarthritis
  • anti-TNF therapy and biologic drugs
  • anti-TNF therapy and biomarkers
  • anti-TNF therapy and biosimilars
  • anti-TNF therapy and bone metabolism
  • Anti-TNF therapy and cancer
  • Anti-TNF therapy and certolizumab pegol
  • anti-TNF therapy and clinical practice
  • anti-TNF therapy and Clinical Response
  • anti-TNF therapy and cytokines
  • anti-TNF therapy and Disease Activity
  • anti-TNF therapy and drug safety
  • anti-TNF therapy and dry eyes
  • anti-TNF therapy and epidemiologic methods
  • anti-TNF therapy and extraarticular manifestations
  • anti-TNF therapy and eye disease
  • anti-TNF therapy and Femur Fractures
  • Anti-TNF therapy and fractures
  • anti-TNF therapy and functional status
  • anti-TNF therapy and Golimumab
  • Anti-TNF therapy and health care cost
  • anti-TNF therapy and Immunotherapy
  • Anti-TNF therapy and infection
  • anti-TNF therapy and inflammation
  • anti-TNF therapy and infliximab
  • Anti-TNF therapy and juvenile idiopathic arthritis (JIA)
  • anti-TNF therapy and magnetic resonance imaging (MRI)
  • anti-TNF therapy and methotrexate (MTX)
  • Anti-TNF therapy and monocytes
  • anti-TNF therapy and neurologic involvement
  • Anti-TNF therapy and pediatric rheumatology
  • anti-TNF therapy and positron emission tomography (PET)
  • anti-TNF therapy and prognostic factors
  • anti-TNF therapy and psoriasis
  • Anti-TNF therapy and psoriatic arthritis
  • anti-TNF therapy and quality of life
  • anti-TNF therapy and radiography
  • anti-TNF therapy and randomized trials
  • anti-TNF therapy and registries
  • anti-TNF therapy and registry
  • anti-TNF therapy and remission
  • anti-TNF therapy and rheumatic disease
  • Anti-TNF therapy and rheumatoid arthritis
  • Anti-TNF therapy and rheumatoid arthritis (RA)
  • Anti-TNF therapy and rituximab
  • anti-TNF therapy and safety
  • anti-TNF therapy and spine involvement
  • Anti-TNF therapy and spondylarthritis
  • Anti-TNF therapy and spondylarthropathy
  • anti-TNF therapy and taper
  • anti-TNF therapy and tnf
  • anti-TNF therapy and tocilizumab
  • anti-TNF therapy and tolerance
  • Anti-TNF therapy and treatment
  • Anti-TNF therapy and tuberculosis
  • anti-TNF therapy and tumor necrosis factor (TNF)
  • anti-TNF therapy and uveitis
  • anti-TNF therapy and vaccines
  • Anti-TNF therapy and vasculitis
  • anti-β2-glycoprotein I Domain1 and IgA isotype
  • antiangiogenetic chemokines and IL-33
  • antibiotic therapy
  • Antibiotics
  • antibiotics and dermatomyositis
  • antibiotics and Electronic Health Record
  • Antibodies
  • antibodies and arthritis
  • antibodies and autoantibodies
  • Antibodies and autoimmune diseases
  • antibodies and big data
  • Antibodies and biomarkers
  • antibodies and citrullination
  • antibodies and diagnosis
  • antibodies and Diagnostic Tests
  • antibodies and flow cytometry
  • antibodies and inflammatory arthritis
  • antibodies and interleukins (IL)
  • antibodies and juvenile idiopathic arthritis-enthesitis (ERA)
  • Antibodies and myositis
  • antibodies and pediatric rheumatology
  • antibodies and pediatrics
  • antibodies and pregnancy
  • antibodies and rheumatic disease
  • antibodies and rheumatoid arthritis (RA)
  • antibodies and scleroderma
  • antibodies and scleroderma-like conditions
  • antibodies and spondylarthropathy
  • antibodies and statin-induced myopathies
  • antibodies and synovial cells
  • antibodies and systemic lupus erythematosus (SLE)
  • antibodies and systemic sclerosis
  • Antibodies and tocilizumab
  • antibodies and tofacitinib
  • antibodies and tolerance
  • antibodies and tumor necrosis factor (TNF)
  • antibodies and vaccines
  • antibodies and vasculitis
  • antibody
  • Antibody microarray
  • antibody microarray and biomarkers
  • Anticardiolipin
  • anticardiolipin and systemic lupus erythematosus (SLE)
  • Anticoagulation
  • Anticoagulation and antiphospholipid
  • Anticoagulation and antiphospholipid syndrome
  • Anticoagulation and systemic lupus erythematosus (SLE)
  • anticoagulation and vasculitis
  • antigen and human leukocyte antigens (HLA)
  • Antigen Bead Array and Enzyme-Linked Immunoabsorbant Assays (ELISA)
  • antigen RA
  • antigen RA and rheumatoid arthritis (RA)
  • antigen specific Th17 cells and enzyme-linked immunospot assay (ELISPOT)
  • antigen-presenting cells
  • antigen-presenting cells and axial spondyloarthritis
  • antigen-presenting cells and myositis
  • antigen-presenting cells and rheumatoid arthritis (RA)
  • antigen-presenting cells and tolerance
  • Antigens
  • antigens and autoantigens
  • antigens and biomarkers
  • antigens and genomics
  • antigens and vasculitis
  • antiinflammatory
  • Antimalarial drugs
  • antimalarial drugs and cardiomyopathy
  • antimalarial drugs and drug toxicity
  • Antimalarial drugs and systemic lupus erythematosus (SLE)
  • antimalarial drugs and treatment
  • Antinuclear antibodies (ANA)
  • Antinuclear antibodies (ANA) and autoantibodies
  • antinuclear antibodies (ANA) and biomarkers
  • Antinuclear antibodies (ANA) and health care cost
  • antinuclear antibodies (ANA) and laboratory tests
  • antinuclear antibodies (ANA) and musculoskeletal disorders
  • antinuclear antibodies (ANA) and systemic sclerosis
  • Antinuclear antibodies (ANA) and thrombosis
  • antinuclear antibodies (ANA) and Utility
  • antinucleosome antibodies
  • Antinucleosome antibodies and autoantibodies
  • Antinucleosome antibodies and systemic lupus erythematosus (SLE)
  • antioxidant
  • antioxidant and MRL-lpr mouse
  • Antioxidants
  • antioxidants and mouse model
  • antioxidants and osteoarthritis
  • antioxidants and osteoclastogenesis
  • Antiphospholipid
  • antiphospholipid and antiphospholipid antibodies
  • antiphospholipid and antiphospholipid syndrome
  • antiphospholipid and microbiome
  • antiphospholipid and monocytes
  • Antiphospholipid and thrombosis
  • antiphospholipid and vasculitis
  • Antiphospholipid antibodies
  • antiphospholipid antibodies and antiphospholipid syndrome
  • antiphospholipid antibodies and aPL
  • antiphospholipid antibodies and biomarkers
  • antiphospholipid antibodies and cardiovascular disease
  • antiphospholipid antibodies and Cell Signaling
  • antiphospholipid antibodies and cerebrovascular disease
  • Antiphospholipid Antibodies and giant cell arteritis
  • antiphospholipid antibodies and interferons
  • Antiphospholipid Antibodies and myocardial involvement
  • Antiphospholipid antibodies and pregnancy
  • Antiphospholipid antibodies and systemic lupus erythematosus (SLE)
  • Antiphospholipid antibodies and systemic sclerosis
  • antiphospholipid antibodies and thrombosis
  • « Previous Page
  • 1
  • 2
  • 3
  • [4]
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next Page »
  • | Last
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences